MA49250A - Nouveaux anticorps anti-cd3 - Google Patents

Nouveaux anticorps anti-cd3

Info

Publication number: MA49250A
Authority: MA; Morocco
Prior art keywords: antibodies; new anti; new
Prior art date: 2017-06-05

Application number

MA049250A

Other languages

English (en)

Inventor

Teddy Beltrametti

Tea Gunde

Christian Hess

Sebastian Meyer

Alexandre Simonin

David Urech

Original Assignee

Numab Therapeutics AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-05

Filing date

2018-06-04

Publication date

2021-04-14

2018-06-04 Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG

2021-04-14 Publication of MA49250A publication Critical patent/MA49250A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MA049250A 2017-06-05 2018-06-04 Nouveaux anticorps anti-cd3 MA49250A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762515293P	2017-06-05	2017-06-05
EP17203832		2017-11-27

Publications (1)

Publication Number	Publication Date
MA49250A true MA49250A (fr)	2021-04-14

Family

ID=62555064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049250A MA49250A (fr)	2017-06-05	2018-06-04	Nouveaux anticorps anti-cd3

Country Status (10)

Country	Link
US (2)	US11319371B2 (fr)
EP (2)	EP3634998B8 (fr)
JP (1)	JP7247110B2 (fr)
KR (1)	KR102651965B1 (fr)
CN (1)	CN110691789A (fr)
AU (2)	AU2018280681B2 (fr)
CA (1)	CA3064163A1 (fr)
ES (1)	ES3015105T3 (fr)
IL (1)	IL271128B2 (fr)
MA (1)	MA49250A (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12098203B2 (en) *	2017-06-05	2024-09-24	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
EP3634998B8 (fr) *	2017-06-05	2025-04-09	Numab Therapeutics AG	Anticorps anti cd3 epsilon
CN120554509A (zh) *	2020-09-27	2025-08-29	嘉和生物药业有限公司	靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
WO2023036326A1 (fr) *	2021-09-13	2023-03-16	江苏先声药业有限公司	Anticorps anti-cd3 humain et son utilisation
CN118510803A (zh) *	2021-10-12	2024-08-16	乐普创一生物科技（上海）有限公司	对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
US20250223358A1 (en) *	2022-03-09	2025-07-10	Antengene Biologics Limited	Novel anti-cd3 antibodies and uses thereof
CN115286715B (zh) *	2022-05-18	2023-05-23	上海百英生物科技股份有限公司	一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
CN116284391B (zh) *	2022-11-16	2023-08-08	艾可泰科(浙江)控股有限公司	使用胰岛干细胞和抗体治疗糖尿病
WO2024155805A2 (fr) *	2023-01-19	2024-07-25	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Anticorps monoclonaux etv1
EP4688832A1 (fr) *	2023-03-29	2026-02-11	Nanjing GenScript Biotech Co., Ltd.	Anticorps et variants de ceux-ci contre le groupe humain de la protéine de différenciation 3

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP1291360A1 (fr)	1991-12-13	2003-03-12	Xoma Corporation	Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
WO1998056915A2 (fr)	1997-06-12	1998-12-17	Research Corporation Technologies, Inc.	Polypeptides d'anticorps artificiels
DK1071752T3 (da)	1998-04-21	2003-10-20	Micromet Ag	CD19xCD3-specifikke polypeptider og anvendelsen deraf
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
EP1940881B1 (fr)	2005-10-11	2016-11-30	Amgen Research (Munich) GmbH	Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
RU2769948C2 (ru)	2007-04-03	2022-04-11	Эмджен Рисерч (Мьюник) Гмбх	CD3-Эпсилон-связывающий домен с межвидовой специфичностью
WO2008119567A2 (fr)	2007-04-03	2008-10-09	Micromet Ag	Domaine de liaison spécifique d'espèces croisées
RU2547600C2 (ru) *	2008-10-01	2015-04-10	Эмджен Рисерч (Мьюник) Гмбх	Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
AU2012245116A1 (en)	2011-04-20	2013-11-07	Genmab A/S	Bispecific antibodies against HER2 and CD3
HK1217023A1 (zh)	2013-05-28	2016-12-16	Numab Innovation Ag	新型抗体
IL243311B (en)	2013-06-26	2022-07-01	Numab Therapeutics AG	New frameworks for antibodies
EP3066133A1 (fr) *	2013-11-04	2016-09-14	Glenmark Pharmaceuticals S.A.	Production de cellules t reciblant des immunoglobulines héréro-dimériques
JP6738285B2 (ja)	2014-05-28	2020-08-12	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体
AU2015292406B2 (en) *	2014-07-25	2021-03-11	Cytomx Therapeutics, Inc	Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
EP2982693A1 (fr) *	2014-08-07	2016-02-10	Affimed Therapeutics AG	Domaine de liaison CD3
MA40894A (fr) *	2014-11-04	2017-09-12	Glenmark Pharmaceuticals Sa	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US20180244777A1 (en) *	2015-05-18	2018-08-30	Numab Therapeutics AG	Novel Treatment Methods Based on Multifunctional Molecules
MX395604B (es)	2015-06-15	2025-03-25	Numab Therapeutics AG	Formato de anticuerpo multiespecífico heterodimérico.
JOP20160154B1 (ar)	2015-07-31	2021-08-17	Regeneron Pharma	أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3634998B8 (fr) *	2017-06-05	2025-04-09	Numab Therapeutics AG	Anticorps anti cd3 epsilon
US12098203B2 (en) *	2017-06-05	2024-09-24	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
EP3816185A1 (fr) *	2019-11-04	2021-05-05	Numab Therapeutics AG	Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
CN116134052A (zh) *	2020-05-29	2023-05-16	努玛治疗有限公司	多特异性抗体
EP3915580A1 (fr) *	2020-05-29	2021-12-01	Numab Therapeutics AG	Anticorps multi-spécifique

2018
- 2018-06-04 EP EP18729644.7A patent/EP3634998B8/fr active Active
- 2018-06-04 IL IL271128A patent/IL271128B2/en unknown
- 2018-06-04 ES ES18729644T patent/ES3015105T3/es active Active
- 2018-06-04 AU AU2018280681A patent/AU2018280681B2/en active Active
- 2018-06-04 CA CA3064163A patent/CA3064163A1/fr active Pending
- 2018-06-04 CN CN201880036701.7A patent/CN110691789A/zh active Pending
- 2018-06-04 JP JP2019566606A patent/JP7247110B2/ja active Active
- 2018-06-04 US US16/619,121 patent/US11319371B2/en active Active
- 2018-06-04 KR KR1020197035542A patent/KR102651965B1/ko active Active
- 2018-06-04 MA MA049250A patent/MA49250A/fr unknown
- 2018-06-04 EP EP25159929.6A patent/EP4541819A3/fr active Pending
2022
- 2022-04-22 US US17/727,449 patent/US20220403028A1/en not_active Abandoned
2025
- 2025-04-16 AU AU2025202700A patent/AU2025202700A1/en active Pending

Also Published As

Publication number	Publication date
JP7247110B2 (ja)	2023-03-28
EP3634998A1 (fr)	2020-04-15
US20220403028A1 (en)	2022-12-22
EP4541819A2 (fr)	2025-04-23
CN110691789A (zh)	2020-01-14
AU2018280681B2 (en)	2025-01-23
CA3064163A1 (fr)	2018-12-13
IL271128B1 (en)	2024-06-01
US20200115449A1 (en)	2020-04-16
AU2025202700A1 (en)	2025-05-08
KR102651965B1 (ko)	2024-03-28
IL271128A (en)	2020-01-30
EP3634998B1 (fr)	2025-02-26
AU2018280681A1 (en)	2019-12-05
EP3634998C0 (fr)	2025-02-26
EP3634998B8 (fr)	2025-04-09
EP4541819A3 (fr)	2025-07-09
ES3015105T3 (en)	2025-04-29
US11319371B2 (en)	2022-05-03
IL271128B2 (en)	2024-10-01
KR20200013233A (ko)	2020-02-06
JP2020522260A (ja)	2020-07-30

Publication	Publication Date	Title
FR24C1056I2 (fr)	2025-10-17	Nouveaux anticorps anti-pd-l1
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
MA52742A (fr)	2021-04-14	Anticorps bispécifiques dll3-cd3
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3334763A4 (fr)	2019-04-03	Nouveaux anticorps anti-pd-1
EP3307777A4 (fr)	2019-02-13	Nouveaux anticorps anti-pd-l1
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
DK3504241T3 (da)	2024-08-19	Anti-cd3-antistofformuleringer
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
MA49250A (fr)	2021-04-14	Nouveaux anticorps anti-cd3
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb